News Janssen's depression drug shows promise in phase 2 Ketamine may be best known as an anaesthetic illegally used as a party drug, but Janssen has shown that it could also be reformulated and used as a treatment for depression.
News Allergan and Gedeon Richter set to expand use of bipolar dru... Companies want Vraylar as option bipolar depression
News Takeda depression app impresses in pilot study App corresponds with standard cognitive and patient-reported assessment measures.
News Lundbeck trial investigates genetic causes of depression New study with 23andMe and Milken Institute looks to determine causes of depression.
News US researchers create AI capable of diagnosing depression Algorithm accurately detects depression from brain scans in 75% of cases.
News Takeda to pilot wearable-based depression app Cognition Kit wearable app measures daily activities and tests cognitive function.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.